Cargando…
High-resolution structures of the bound effectors avadomide (CC-122) and iberdomide (CC-220) highlight advantages and limitations of the MsCI4 soaking system
Cereblon (CRBN) is the substrate receptor of the CRL4(CRBN) E3 ubiquitin ligase and is a central player in targeted protein degradation. It is the target of the thalidomide-derived immunomodulatory drugs (IMiDs) and is one of the most widely employed receptors for proteolysis-targeting chimeras (PRO...
Autores principales: | Heim, Christopher, Hartmann, Marcus D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International Union of Crystallography
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8900816/ https://www.ncbi.nlm.nih.gov/pubmed/35234143 http://dx.doi.org/10.1107/S2059798322000092 |
Ejemplares similares
-
Phase Ib study of combinations of avadomide (CC‐122), CC‐223, CC‐292, and rituximab in patients with relapsed/refractory diffuse large B‐cell lymphoma
por: Ribrag, Vincent, et al.
Publicado: (2022) -
Phase Ib study of avadomide (CC‐122) in combination with rituximab in patients with relapsed/refractory diffuse large B‐cell lymphoma and follicular lymphoma
por: Nastoupil, Loretta J., et al.
Publicado: (2022) -
P07: RESULTS FROM THE CC-220-MM-001 DOSE-EXPANSION PHASE OF IBERDOMIDE PLUS DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: van de Donk, N. W. C. J, et al.
Publicado: (2022) -
Population Pharmacokinetics of CC-122
por: Cheng, Yiming, et al.
Publicado: (2021) -
Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN
por: Bjorklund, Chad C., et al.
Publicado: (2019)